<code id='32AE9E4C4A'></code><style id='32AE9E4C4A'></style>
    • <acronym id='32AE9E4C4A'></acronym>
      <center id='32AE9E4C4A'><center id='32AE9E4C4A'><tfoot id='32AE9E4C4A'></tfoot></center><abbr id='32AE9E4C4A'><dir id='32AE9E4C4A'><tfoot id='32AE9E4C4A'></tfoot><noframes id='32AE9E4C4A'>

    • <optgroup id='32AE9E4C4A'><strike id='32AE9E4C4A'><sup id='32AE9E4C4A'></sup></strike><code id='32AE9E4C4A'></code></optgroup>
        1. <b id='32AE9E4C4A'><label id='32AE9E4C4A'><select id='32AE9E4C4A'><dt id='32AE9E4C4A'><span id='32AE9E4C4A'></span></dt></select></label></b><u id='32AE9E4C4A'></u>
          <i id='32AE9E4C4A'><strike id='32AE9E4C4A'><tt id='32AE9E4C4A'><pre id='32AE9E4C4A'></pre></tt></strike></i>

          Home / hotspot / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:7271

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In